# Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct05061550/  
OnCo record `nct05061550` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Durvalumab, Oleclumab, Monalizumab in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, now recruiting.

## Summary

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT05061550 by AstraZeneca, with 630 participants planned, started 2022-04-14 and due to reach its primary completion in 2030-05-28. Interventions recorded: Durvalumab, Oleclumab, Monalizumab, Dato-DXd, AZD0171. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05061550
- Phase: 2
- Setting: A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)
- Sponsor: AstraZeneca
- Enrolled: 630

## Sources

- ClinicalTrials.gov NCT05061550: https://clinicaltrials.gov/study/NCT05061550

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Monalizumab](https://onco.cc/drugs/monalizumab/), [Oleclumab](https://onco.cc/drugs/oleclumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct05061550.json